E-Mail
IMAGE: Liu and his lab engineered botulinum toxin to target new proteins, a critical advance that could lead to new treatments for a range of maladies, including nerve and brain damage,. view more
Credit: Casey Atkins Photography, courtesy of Broad Institute
When people hear botulinum toxin, they often think one of two things: a cosmetic that makes frown lines disappear or a deadly poison.
But the miracle poison, as it s also known, has been approved by the F.D.A. to treat a suite of maladies like chronic migraines, uncontrolled blinking, and certain muscle spasms. And now, a team of researchers from Harvard University and the Broad Institute have, for the first time, proved they could rapidly evolve the toxin in the laboratory to target a variety of different proteins, creating a suite of bespoke, super-selective proteins called proteases with the potential to aid in neuroregeneration, regulate growth hormones, calm rampant inflammation, or dampen the life-
E-Mail
IMAGE: Evan Y. Snyder, M.D., Ph.D., professor and founding director of the Center for Stem Cells and Regenerative Medicine at Sanford Burnham Prebys Medical Discovery Institute. view more
Credit: Sanford Burnham Prebys Medical Discovery Institute
LA JOLLA, CALIF. - Feb. 23, 2021 - The American Institute for Medical and Biological Engineering (AIMBE) has elected to its College of Fellows Evan Y. Snyder, M.D., Ph.D., professor and founding director of the Center for Stem Cells and Regenerative Medicine at Sanford Burnham Prebys Medical Discovery Institute. Snyder was nominated, reviewed, and elected by his peers and members of the College of Fellows for his seminal contributions to regenerative medicine. He will be inducted to AIMBE during a formal ceremony held on March 26, 2021.
ROCKVILLE, MD - A tenth of all intensive care unit patients worldwide, and many critical patients with COVID-19, have acute respiratory distress syndrome (ARDS).
E-Mail
Oak Brook, IL - The Society for Laboratory Automation and Screening (SLAS) is pleased to announce a collaboration with the Pistoia Alliance to support and promote innovative life sciences start-ups and emerging companies.
The SLAS Ignite Program is a multi-pronged initiative to promote innovation, pioneering research, start-up and emerging companies and their products, and commercialization and collaboration opportunities for all involved. Through Innovation AveNEW and the Ignite Award, Ignite Academic Collaborations and other activities, SLAS underscores its foundational commitment to enabling scientists, academic researchers and business development professionals to build relationships as potential strategic partners.
The Pistoia Alliance is a global organization made up of life science companies, technology and service providers, publishers, and academic groups working together to lower barriers to innovation in life science and healthcare R&D. Its President s Start